Disease Control and Voice Outcomes Following Treatment With PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis.
Amir Kaskas, Janet Valdez, Scott Napier and 3 others
PMID 40307073WHAT IT FOUND
In adults with recurrent respiratory papillomatosis, patients who responded well to PRGN-2012 gene therapy saw significant drops in both visible papilloma disease and self-reported voice handicap.
Fewer lifetime surgeries before treatment correlated with better voice outcomes, though the study was small.
Key findings
01Complete responders to PRGN-2012 showed significantly greater reductions in both papilloma disease burden (Derkay score) and voice handicap (VHI-10 score) compared to non-responders.
02Among complete responders, those who had required fewer lifetime surgical interventions before treatment experienced greater reductions in voice handicap.
03Disease severity before treatment (number of surgeries in the prior year or total lifetime surgeries) did not consistently predict which patients would respond to PRGN-2012.
STILL TO COME
How it was doneWhat they foundWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study was a post-hoc analysis of a small, single-arm trial (n=38), limiting the generalizability of the findings. The sample size for subgroup analyses (e.g., the 18 complete responders) was too small to perform multivariate adjustments, meaning other factors could have influenced the voice outcomes. The Derkay score, used to measure disease burden, is not routinely used in clinical practice to determine when surgery is needed, which may affect the clinical applicability of the disease-burden correlations. Voice handicap was measured using a self-report tool (VHI-10), which is subjective and can be influenced by factors other than physical laryngeal status.
Declared interests
The authors declare that no conflicts of interest exist.
The easy way to misread this
Do not assume that PRGN-2012 will fully restore voice quality in patients with a long history of multiple surgeries. While the therapy can control disease growth, patients with many lifetime interventions may have residual voice handicap due to prior surgical effects, and this analysis does not prove that the therapy reverses existing laryngeal damage.